Department of Surgery, International University of Health and Welfare, Mita Hospital, Mita 1-4-3, Minato-ku, Tokyo, Japan.
Anticancer Res. 2011 Nov;31(11):3983-9.
We report a case of anal cancer in a 58-year-old woman who complained of narrow, bloody stools and anal pain. Physical examination revealed anal stenosis associated with a circular mass arising in the anal canal. Histological examination of biopsy specimens confirmed a diagnosis of moderately differentiated squamous cell carcinoma. Enhanced computed tomography revealed anal cancer invading the levator ani and the vagina, with lymph-node, multiple hepatic, and pulmonary metastases. The patient received two cycle of chemoradiotherapy with S-1 plus low-dose cisplatin with rest for 4 weeks, leading to complete response of the primary lesion and a partial response of the metastatic lesions. Each cycle included oral S-1 (120 mg/body; day 1-21), cisplatin (10 mg/body; day 1-5, 8-12) and radiotherapy (2 Gy/day; day 1-5, 8-12, 15-19). Adverse effects of treatment were mild perineal skin erosion and mild appetite loss, but no hematologic toxicity. Although the patient died 16 months after first admission, chemoradiotherapy with S-1 plus cisplatin is potentially effective for the management of advanced anal cancer.
我们报告一例 58 岁女性肛门癌病例,该患者主诉排便变细伴肛门疼痛,伴有血便。体格检查发现肛门狭窄,伴有环状肿块位于肛门直肠内。活检标本的组织学检查证实为中分化鳞状细胞癌。增强 CT 显示肛门癌侵犯肛提肌和阴道,伴有淋巴结、多肝和肺转移。患者接受了 S-1 加低剂量顺铂化疗 2 个周期,休息 4 周,导致原发灶完全缓解,转移灶部分缓解。每个周期包括口服 S-1(120mg/体;第 1-21 天)、顺铂(10mg/体;第 1-5 天、8-12 天)和放疗(2Gy/天;第 1-5 天、8-12 天、15-19 天)。治疗的不良反应为轻度会阴皮肤侵蚀和轻度食欲下降,但无血液学毒性。尽管患者在首次入院后 16 个月死亡,但 S-1 加顺铂化疗对晚期肛门癌的治疗具有潜在疗效。